Vimpat® (lacosamide) – Expanded indication

- On October 14, 2021, the FDA approved UCB's Vimpat (lacosamide), for the treatment of partial-onset seizures in patients 1 month of age and older.
    - Vimpat was previously approved for this indication in patients 4 years of age and older.
- Vimpat is also approved as adjunctive therapy in the treatment of primary generalized tonic-clonic seizures in patients 4 years of age and older.
- Vimpat is a Schedule V controlled substance.
- The use of Vimpat in pediatric patients 1 month to less than 17 years of age is supported by evidence from adequate and well-controlled studies of Vimpat in adults with partial-onset seizures, pharmacokinetic data from adult and pediatric patients, and safety data in 847 pediatric patients 1 month to less than 17 years of age.
- The recommended dosage of Vimpat for monotherapy and adjunctive therapy for partial-onset seizures in patients 1 month of age and older is dependent on body weight. Dosage should be increased based on clinical response and tolerability, no more frequently than once per week.
- Refer to the Vimpat drug label for complete dosing information for partial-onset seizures and for dosing in primary generalized tonic-clonic seizures.